Trial Profile

Safety of canagliflozin in diabetic patients with chronic heart failure: randomized, non-inferiority trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2023 Results assessing correlation of changes in hematocrit and hemoglobin with cardiac and renal improvement for Canagliflozin through week 26 published in the Journal of Cardiovascular Pharmacology
01 Jan 2023 Results (n=233) of a post-hoc analysis assessing effects of SGLT2 inhibition on distinct subsets of body fluid volume in patients with CHF and T2D published in the Clinical Research in Cardiology
18 Apr 2022 Results of exploratory meditation analysis assessing mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration, published in the Diabetes, Obesity and Metabolism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com